久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Innovation

Dedication, team work boost China's COVID-19 research

Xinhua | Updated: 2022-03-29 14:33
Share
Share - WeChat
Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. [Photo provided to chinadaily.com.cn]

BEIJING -- Many clinicians have referred to a COVID-19 drug developed by Zhang Linqi as a "miracle medicine" after seeing their patients' lasting fever symptoms diminish quickly following an injection of the drug.

A virologist at China's Tsinghua University, Zhang led his team to create a cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which cut hospitalizations and deaths by 80 percent in human trials and appears to work well against all existing variants.

It took just 18 months for the Chinese drug to be developed and receive regulatory approval.

"In less than two years, we finished a job that would otherwise take at least 10 years," Zhang said.

His latest research uses a deep learning approach to help his team obtain antibodies that can neutralize the coronavirus and its variants at a faster pace.

Anti-COVID-19 research results from Chinese institutes, universities and enterprises have been published in international academic journals every two or three days since January. Chinese scientists are contributing their wisdom, experience and painstaking efforts to enhance the human capacity to cope with the deadly virus.

While the Academy of Military Medical Sciences presented an mRNA COVID-19 antibody that provided lasting immunity in mice, Fudan University created an adenovirus vaccine candidate designed to give dual protection against both COVID-19 and influenza viruses.

Researchers at the Chinese Academy of Sciences (CAS), China's top academic institute, are working on an inhalable antibody with low cost and large-scale production advantages, while pharmaceutical companies in Shanghai and Suzhou have commenced global trials of a co-developed oral drug for moderate and severe COVID-19 cases.

Speaking to press at the fifth session of the 13th National People's Congress earlier in March, Minister of Science and Technology Wang Zhigang said that China has had fruitful beginning to its development of COVID-19 vaccines and drugs, with several candidates being granted market approval or undergoing clinical trials.

"The more tools to tackle COVID-19 that science and technology can provide, the better our anti-pandemic measures can become," the minister said.

None of this progress has come easily. China's impressive pace of medical research is the result of the long-term hard work of Chinese scientists.

Wang Qihui is a CAS virologist. Since January 2020, when Wang first volunteered to work on COVID-19, she has been racing against the clock to find ways to defeat the virus.

Tasked with finding effective antibodies in a short time, Wang led her team to conduct experiments day and night. She once stayed in her laboratory for two weeks, sometimes forgetting food and sleep.

Five months after the initial outbreak of the novel coronavirus, her team announced that JS016, a COVID-19-neutralizing antibody that they had developed, could be administered to healthy people in clinical trials. In November last year, the antibody was granted emergency-use authorization in 15 countries, including the United States and several European countries.

Lots of sacrifices were made in this process. Right before the results of the COVID-19 antibody study came out, Wang Qihui experienced neurological deafness because of high stress, which led to temporary hearing loss in her left ear.

She was hospitalized for five days after a doctor warned her that, in the absence of timely treatment, she could develop permanently impaired hearing.

The scientist has since recovered and is determined to make greater contribution to the fight against the pandemic. She has resumed her COVID-19 research, working to develop a nasal spray antibody drug and an mRNA vaccine.

Wang Qihui attributes her achievements largely to her previous experience in the field of viral infectious diseases, such as Middle East Respiratory Syndrome (MERS) and the Zika virus.

Zhang Linqi and his team, like Wang, have used their determination and wealth of experience in responding to new pathogens to deal with the pandemic.

Zhang has devoted 30 years to the study of HIV-1 pathogenesis and vaccine development, and to emerging and re-emerging human viral pathogens such as MERS, Ebola and the Zika virus.

"The development of a treatment drug and a vaccine sounded lighting fast, even to me, but it benefited from years of research on antibody drugs and HIV vaccine development," Zhang said when asked how the COVID-19 antibody drug he developed was created so quickly.

Inspired by the "AIDS cocktail," a combination treatment of three or four different medicines for people with HIV/AIDS, Zhang and his team selected 206 monoclonal antibodies and whittled the number down to two, creating their COVID-19 cocktail therapy.

It has demonstrated an improved performance in resisting virus mutations and maintained longer activity in the human body compared to similar therapies consisting of only one antibody.

Xiamen University, which has also accumulated significant experience in vaccine development, is a major research force in the fight against COVID-19. It was also one of the first institutions to receive global virus research donations.

Emerging technologies are involved in COVID-19 research. Tech giant Baidu has licensed its mRNA sequencing algorithm to French vaccine maker Sanofi for use in the design of COVID-19 vaccines and therapeutic products. According to the Chinese company, the algorithm can accelerate the research.

Zhang also stressed that interdisciplinary collaboration is very important in his work. He collaborated with Tsinghua biologists to decipher the structure of the virus, and with Shenzhen clinicians to isolate monoclonal antibodies in convalescent patients. These partnerships accelerated the development of China's first COVID-19 antibody drug.

"Scientific research is to explore the unknown in blind zones. We scientists not only need strong hearts and big brains, but also partners to support us. Even if we fail, we are not alone, as there are many people supporting us," Zhang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    日韩久久一级片| 成年丰满熟妇午夜免费视频| 糖心vlog在线免费观看| 久草资源站在线观看| 在线无限看免费粉色视频| 日韩视频第二页| 国产 国语对白 露脸| 亚洲欧美久久久久| 日韩视频免费播放| 大地资源第二页在线观看高清版| 国产成人精品视频免费看| 中国一级大黄大黄大色毛片| 一级片视频免费观看| 丝袜老师办公室里做好紧好爽| 最新av网址在线观看| 亚洲这里只有精品| aa免费在线观看| www.avtt| 红桃一区二区三区| 一区二区久久精品| 国产一区二区在线免费播放| 亚洲精品无码久久久久久| 国产aaa免费视频| 欧美日韩一级在线| 肉色超薄丝袜脚交| 亚洲另类第一页| 色哟哟精品视频| 99爱视频在线| 免费成人午夜视频| 欧美视频在线观看视频| 国产精品igao激情视频| 久久久久久久久久久久久国产| 国产小视频精品| 999精品视频在线| 成人在线免费播放视频| 国产又大又硬又粗| 人妻有码中文字幕| 国语对白做受xxxxx在线中国| 免费无码不卡视频在线观看| r级无码视频在线观看| 欧美另类videosbestsex日本| 色一情一乱一乱一区91| 成年人视频大全| 中国一级大黄大黄大色毛片| 三上悠亚免费在线观看| 水蜜桃在线免费观看| 日韩中文在线字幕| www.亚洲成人网| 国产精品久久久久久久乖乖| 丁香六月激情婷婷| 欧美 日韩 国产 高清| 日本www在线播放| 激情五月开心婷婷| 日本a√在线观看| 日韩欧美国产片| 婷婷激情小说网| 黄色影视在线观看| 久久久久久久久久毛片| 91看片在线免费观看| wwwwwxxxx日本| 色综合五月婷婷| 四虎免费在线观看视频| 800av在线免费观看| 久久综合九色综合88i| 国产日韩一区二区在线观看| 青青在线视频免费| 国产又黄又猛的视频| 手机看片日韩国产| 免费拍拍拍网站| 三级4级全黄60分钟| 久久国产激情视频| 国产免费一区二区三区四在线播放 | 50路60路老熟妇啪啪| 天天色综合天天色| 一区二区三区一级片| 大伊香蕉精品视频在线| 免费观看成人在线视频| 亚洲男人天堂av在线| 欧美精品在欧美一区二区| 草草久久久无码国产专区| 香蕉视频禁止18| 日韩一级特黄毛片| 妞干网在线免费视频| 亚洲自拍第三页| 亚洲熟妇无码另类久久久| 波多野结衣xxxx| 日本人妻伦在线中文字幕| 色诱视频在线观看| 在线免费黄色小视频| 欧美日韩亚洲一| 黄色a级片免费看| 日韩精品视频久久| 欧在线一二三四区| 公共露出暴露狂另类av| 免费黄色福利视频| 五月天国产视频| 日本日本19xxxⅹhd乱影响| 中文字幕 日韩 欧美| 久久99中文字幕| 污污网站免费观看| 男人日女人逼逼| 日本一本在线视频| 欧美日韩中文在线视频| 日韩视频一二三| 在线观看av网页| 奇米影视亚洲色图| 国产精品99久久久久久大便| 日本黄网站免费| 无码熟妇人妻av在线电影| 在线观看免费视频高清游戏推荐| 国产玉足脚交久久欧美| 午夜视频在线网站| 日韩 欧美 高清| 日韩 欧美 视频| 1314成人网| 成年网站在线播放| 99精品在线免费视频| 欧美一级黄色录像片| 天天色综合天天色| 黄www在线观看| 欧美中文字幕在线观看视频| 色婷婷一区二区三区在线观看| 日本精品一区二区三区四区| 丰满的少妇愉情hd高清果冻传媒| 久久成年人网站| 黄色在线视频网| 红桃av在线播放| 国产精品又粗又长| 欧美黄网在线观看| 亚洲小说欧美另类激情| 四季av一区二区三区| 日本www.色| 久久久久久久久久久福利| 五十路熟女丰满大屁股| 福利在线小视频| 久久久国产精华液999999 | 日韩高清在线一区二区| 亚洲欧美在线精品| 国产xxxxx在线观看| 国产特级黄色大片| 麻豆tv在线播放| 免费看黄在线看| 91黄色在线看| 国内少妇毛片视频| 99热久久这里只有精品| www插插插无码免费视频网站| 国内精品国产三级国产aⅴ久| 在线免费看污网站| 亚洲免费999| 在线观看免费不卡av| 孩娇小videos精品| 亚洲精品性视频| 五月天激情播播| 国产毛片久久久久久| 国产不卡的av| 992tv成人免费观看| 一道本在线观看视频| 麻豆一区二区三区在线观看| japanese在线视频| 黄色一级片av| 国产欧美精品aaaaaa片| 久久成人福利视频| 亚洲中文字幕无码专区| av免费中文字幕| 日本美女高潮视频| www.久久91| 免费国产成人看片在线| 亚洲中文字幕无码一区二区三区| av日韩在线看| 青青艹视频在线| 成年人在线观看视频免费| 国产成人在线综合| 国产人妻互换一区二区| 久久99久久久久久| 成人黄色片视频| 国产原创精品在线| 日本丰满大乳奶| 婷婷无套内射影院| 亚洲精品高清无码视频| 久久久精品高清| 黄色a级片免费看| 黄色影院一级片| 黄大色黄女片18第一次| 欧美三级午夜理伦三级老人| 你真棒插曲来救救我在线观看| 成年人免费大片| 中文字幕亚洲影院| 欧美亚洲黄色片| 茄子视频成人免费观看| 182午夜视频| 久久视频这里有精品| 色综合天天色综合| 国产制服91一区二区三区制服| 337p粉嫩大胆噜噜噜鲁| 91女神在线观看| 欧美亚洲黄色片| 爱情岛论坛亚洲首页入口章节| 男同互操gay射视频在线看| 毛片在线视频播放| www,av在线|